Candel Therapeutics (CADL) Other Operating Expenses (2024 - 2025)
Candel Therapeutics (CADL) posted Other Operating Expenses of $10.3 million for Q4 2025, up 2415.8% sequentially from -$443000.0 in Q3 2025, and up 31.95% YoY from $7.8 million in Q4 2024.
Candel Therapeutics (CADL) Other Operating Expenses (2024 - 2025) Analysis & Trends
Candel Therapeutics has reported Other Operating Expenses for 2 years, with the latest figure at $10.3 million in Q4 2025.
- Quarterly Other Operating Expenses rose 31.95% year-over-year to $10.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $11.7 million (down 8.86% YoY) and the FY2025 annual result came in at $27.7 million, up 64.44% from the prior year.
- Other Operating Expenses improved to $10.3 million in Q4 2025 per CADL's latest filing, from -$443000.0 in the prior quarter.
- Over five years, Other Operating Expenses peaked at $10.3 million in Q4 2025 and troughed at -$517000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Candel Therapeutics | 643.41 Mn | 643.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 10.26 Mn |
| Sep 30, 2025 | -443,000.00 |
| Jun 30, 2025 | -462,000.00 |
| Mar 31, 2025 | 2.31 Mn |
| Dec 31, 2024 | 7.78 Mn |
| Sep 30, 2024 | 2.75 Mn |
| Jun 30, 2024 | -517,000.00 |
| Mar 31, 2024 | 2.78 Mn |